Click on the “Search Now” button to search for research studies enrolling people like you. Need help getting started? Click on “Tips for Searching Studies” to find resources and assistance to help you find studies.

Search Results: Treatment + Endometrial Cancer (7 results)

1 through 7 of 7
PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)

Treatment
Any advanced or metastatic solid tumor except ovarian or prostate

PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)

PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.

More info
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

Treatment
Advanced solid tumors

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

More info
Retifanlimab Alone or with Other Agents for Advanced Endometrial Cancer that Progressed with Platinum

Treatment
Advanced endometrial cancer

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.

More info
CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations

Treatment
Advanced solid tumors

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

This study will look at safety and affectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

More info
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

More info
Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer

Treatment

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High.

More info
A Study of Nivolumab in Selected Uterine Cancer Patients

Treatment

A Study of Nivolumab in Selected Uterine Cancer Patients

The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer. 

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

More info
Additional Results on Clinicaltrials.gov Treatment + Endometrial Cancer
98 results
Clinical Trial Official Title
NCT04683653 Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04386993 De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT03935256 Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
NCT05139368 Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT03932409 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT04458402 Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT03955978 TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT04570553 Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT04839614 Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT04586959 Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT04970368 Comparison of Nodal Staging in Endometrial Cancer
NCT04743999 Evaluation of Quality of Life Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
NCT04774419 Radiation and Dostarlimab in People With Endometrial Cancer After They Receive Surgery
NCT03785288 Vaginal Cuff Brachytherapy Fractionation Study
NCT04025229 High Intensity Interval Training in Endometrial Cancer
NCT03694834 Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
NCT04514692 Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT04527900 The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT00924027 A Study of Patients Receiving High-Dose Rate Brachytherapy
NCT03671811 Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
NCT04567771 Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity Modulated Radiation Therapy After Surgery for the Treatment of Endometrial or Cervical Cancer
NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04049227 Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
NCT03835819 A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT04576104 Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT05419817 Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
NCT03968406 Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT04997096 Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT05036681 A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT05032040 A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05112601 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT05107739 A Study of DeTIL-0255 in Adults With Advanced Malignancies
NCT04585958 Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
NCT03120624 VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer
NCT03617679 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
NCT05194735 Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
NCT05039801 IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT05263492 Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
NCT03832361 Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
NCT04512144 Mindfulness in Endometrial and Cervical Cancer
NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04660929 CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT02912572 Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04298827 Gyn Onc Prehab Study
NCT03660826 Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT05092373 Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT03914612 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT04269200 Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04719273 Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
NCT03675893 Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
NCT05173987 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05082025 Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04704661 Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT03008408 A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
NCT05277051 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT04491942 Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT04486352 A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
NCT05156268 A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT04586335 Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
NCT04080284 Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT04196257 BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT03909152 A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
NCT04188548 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT04344795 Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
NCT03586661 Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05150691 A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT02397083 Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
NCT03065062 Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT04044859 ADP-A2M4CD8 as Monotherapy or in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT03643510 Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT03667716 COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
NCT05169437 Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05252416 (VELA) Study of BLU-222 in Advanced Solid Tumors
NCT02922764 A Study of RGX-104 in Patients With Advanced Solid Malignancies
NCT05069935 FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT02584478 Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
NCT04485013 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT02521844 A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
NCT05548296 A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT02635672 Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
NCT04300556 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04319757 ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT04570839 COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT05086692 A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
NCT04458259 Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Research Search Tool Sponsored By:

Merck & Co., Inc.

This resource was made possible through an independent grant from Merck & Co., Inc.